This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Options Traders Expect Huge Moves in Tilray (TLRY) Stock
by Zacks Equity Research
Tilray (TLRY) needs investors to pay close attention to the stock based on moves in the options market lately.
Is the Options Market Predicting a Spike in Tilray (TLRY) Stock?
by Zacks Equity Research
Investors need to pay close attention to Tilray (TLRY) stock based on the movements in the options market lately.
Zacks Investment Ideas feature highlights: Tilray, Canopy and Cronos
by Zacks Equity Research
Zacks Investment Ideas feature highlights: Tilray, Canopy and Cronos
Intrexon Signs Licensing Agreement with Next Green Wave
by Zacks Equity Research
Intrexon (XON) partners with Next Green Wave Holdings to utilize Intrexon's Botticelli next-generation plant propagation platform.
A Week of Cannabis Investing Deals & Earnings Reports from GS, BAC, UAL
by Ryan McQueeney
Ryan McQueeney covers the latest Brexit news and Snap's executive exodus. He also recaps earnings results from Goldman Sachs, Bank of America, and United Air Lines. Later, he discusses a busy week for deals in the cannabis industry.
Tilray Teams Up With Authentic Brands, Stock Down on Sell-Off
by Zacks Equity Research
Tilray (TLRY) signs a marketing agreement with Authentic Brands Group to sell consumer cannabis products.
Why Did Tilray (TLRY) Stock Drop Sharply Today?
by Ryan McQueeney
Shares of Tilray (TLRY) fell more than 17% on Tuesday after its post-IPO lockup period expired, allowing early investors in the Canadian marijuana company to cash out of their positions for the first time.
Tilray's Tuesday Slide Due to IPO Lockup Expiration
by David Borun
Tilray's biggest shareholder resolves to stay long for the foreseeable future
Tilray Shares Rally as Investor Plans Not to Sell Shares
by Zacks Equity Research
Tilray (TLRY) gains after Privateer Holdings decides not to sell shares in the first half of 2019.
Tilray, Inc. (TLRY) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Tilray, Inc. (TLRY) closed the most recent trading day at $80.40, moving +0.88% from the previous trading session.
Zacks Market Edge Highlights: Tilray, Constellation Brands, Altria and GW Pharmaceuticals
by Zacks Equity Research
Zacks Market Edge Highlights: Tilray, Constellation Brands, Altria and GW Pharmaceuticals
Pot Stocks in 2019: A Year of Transition
by Tracey Ryniec
In 2018, investors pinned their pot stock hopes on Canadian legalization but in 2019 the game has changed. Who will emerge as the winners?
Softness in Beer Hurt Alcohol Stocks, Can Cannabis Change Fate?
by Zacks Equity Research
The alcohol space continues its struggles against soft beer sales and higher costs. Meanwhile, cannabis-infused drinks are gaining popularity.
Tilray Gains More Than 200%: Is There More Scope for Growth?
by Zacks Equity Research
Tilray (TLRY) gains more than 200% in the past six months. Strategic deals should propel further growth.
Tilray, Inc. (TLRY) Stock Moves -0.65%: What You Should Know
by Zacks Equity Research
In the latest trading session, Tilray, Inc. (TLRY) closed at $70, marking a -0.65% move from the previous day.
Does AB InBev (BUD) Stock Have Potential to Rebound in 2019?
by Zacks Equity Research
AB InBev (BUD) suffers on account of softness in the beer industry, particularly in the United States, which is hurting its sales. However, its recent venture in cannabis space is encouraging.
5 Best-Performing IPOs of 2018
by Nitish Marwah
Strong economic fundamentals and increased foreign investment have led to such a high number of companies going public.
Company News For Dec 21, 2018
by Zacks Equity Research
Companies In The News Are: WBA,BB,CCL,TLRY,BUD
Do Options Traders Know Something About Tilray (TLRY) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Tilray (TLRY) stock based on the movements in the options market lately.
AB InBev (BUD) Enters Booming Cannabis Realm With Tilray Deal
by Zacks Equity Research
AB InBev (BUD) announces partnership with the leading marijuana producer, Tilray.
Tilray Stock Up on Medical Cannabis Collaboration With Sandoz
by Zacks Equity Research
Tilray (TLRY) expands its previous collaboration deal with Sandoz, a generic arm of Novartis, to supply medical cannabis globally using the latter's supply chain.
Company News For Dec 19, 2018
by Zacks Equity Research
Companies In The News Are: CBS,BA,DRI,TLRY,NVS
What's In Store for GE in 2019? & Tuesday's Trending Stocks: TLRY, JNJ, ORCL
by Ryan McQueeney
Ryan McQueeney recaps news involving the U.S. housing market, Tilray, Johnson & Johnson, and Oracle. Later, the host provides an outlook for General Electric stock in 2019.
Tilray, Inc. (TLRY) Stock Moves -0.52%: What You Should Know
by Zacks Equity Research
Tilray, Inc. (TLRY) closed at $75.13 in the latest trading session, marking a -0.52% move from the prior day.
4 Reasons Why Pot Stocks & ETF Could Be on a High in 2019
by Sanghamitra Saha
These are the factors that could send marijuana stocks and ETF high in 2019.